Clinical trials: Inhalation Spacers
Asthma Childhood, Asthma
Advancing Diagnosis and Treatment of Pediatric Asthma
Asthma is one of the most common chronic diseases in children, and treatment success often depends on proper inhaler use and consistent medication adherence.
- Conditions
- Asthma Childhood, Asthma, Inhalation Spacers
- Trial name
- Care4Asthma (NCT07500246)
- Testing
- Whizz spacer system, AeroChamber Plus® Flow-Vu®
- Where
- Luxembourg
- Volunteers
- 208 people
- Sponsor
- Luxembourg Institute of Health
Asthma
Impact of Anti-static Chamber/Mask
To compare lung delivery of fluticasone propionate delivered by HFA-pMDI, using a conventional polycarbonate of anti-static chamber/mask in a randomized crossover design in 1-6 year old children.
- Trial name
- NCT00307970
- Testing
- HFA FP MDI, conventional chamber/mask; anti-static chamber/mask
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
Chronic Obstructive Pulmonary Disease
A Study to Assess the Pharmacokinetics and Safety of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-Generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
This study aims to assess the effect on total systemic exposure and to characterize exposure BGF MDI HFO with a spacer compared to without a spacer; also, to demonstrate that total systemic exposure of BGF when administered as…
- Trial name
- NCT06297668
- Testing
- Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COPD
Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients
The study is performed to investigate the effect of the spacing device on the pharmacokinetics of CHF 5993 pMDI active ingredients administered with and without Aerochamber Plus Flow-vu antistatic VHC spacer as a single…
- Trial name
- TRIPLE 4 (NCT02119234)
- Testing
- Beclometasone/formoterol/glycopyrrolate
- Where
- Poland
- Volunteers
- 36 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Inhaler Adherence and Inhalation Technique Assessed by a Smart Spacer in Patients with Severe Asthma on Biologics
Severe refractory asthma affects about 3.5% of asthma patients, often necessitating biologic therapy in addition to standard treatment.
- Trial name
- OUTERSPACE-3 (NCT06360393)
- Testing
- Smart spacer
- Where
- 5 sites in Netherlands
- Volunteers
- 110 people
- Sponsor
- University Medical Center Groningen
Asthma
Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old
The rationale is to investigate the systemic availability of BDP/B17MP and formoterol after single oral inhalation of CHF 1535 50/6 pMDI vs the free combination of approved BDP and Formoterol pMDIs, in asthmatic children (5 to 11…
- Trial name
- PAED1 (NCT01848769)
- Testing
- CHF1535 pMDI + AC Plus, BDP + AC Plus, Formoterol + AC Plus
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS
Collect PK/PD data for this age group to compare ADVAIR DISKUS with ADVAIR HFA
- Trial name
- NCT00400608
- Testing
- ADVAIR HFA, ADVAIR DISKUS
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Healthy
A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer
The primary purpose of this study is to demonstrate the equivalence of budesonide, glycopyrronium, formoterol (BGF) metered dose inhaler (MDI) hydrofluoroolefin (HFO) with a spacer to BGF MDI hydrofluoroalkane (HFA) with a…
- Trial name
- NCT06340581
- Testing
- Treatment A: BGF MDI HFA, Treatment B: BGF MDI HFO, Treatment C: BGF MDI HFO
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects
The purpose of this study is to address an Food Drug and Administration (FDA) request to provide safety data in pre-asthmatic patients, ages 6 months to <12 months, following administration of fluticasone propionate HFA.
- Trial name
- NCT00370097
- Testing
- FLOVENT (fluticasone propionate) HFA
- Where
- 7 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Patient Compliance, Inhalation Spacers
Animated Cartoons and Cooperation in Young Children Receiving Inhaled Medications
Up to 50% of infants and young children cry during the administration of their inhaled treatment for their asthma. This results in decreased lung deposition, and thus decreased effectiveness of their inhaled treatment.
- Trial name
- DISTRACT (NCT02879240)
- Testing
- Animated Cartoon, Black screen
- Where
- 3 sites in France
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Hôpital Necker-Enfants Malades
Chronic Obstructive Pulmonary Disease (COPD)
Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
Study comparing the same drugs as a dual combination product (budesonide and formoterol) given via two different inhalers. To see which one results in the best effect on breathing.
- Trial name
- NCT04078126
- Testing
- BFF, Symbicort Turbuhaler
- Where
- 4 sites in Germany
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Cough, Wheezing
A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy
This is an open-label, non-drug methodology trial in which subjects undergo a stepwise series of tests to evaluate their ability to use a mouthpiece to deliver nebulized therapy.
- Trial name
- NCT04011709
- Testing
- VR647 Inhalation System + VR647 Smart Card 3 Secs, VR647 Inhalation System + VR647 Smart Card 2 Secs, VR647 Inhalation System + VR647 Smart Card 4 Secs
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Vectura Limited